Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells
- PMID: 17181570
- DOI: 10.1111/j.1365-2362.2007.01746.x
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells
Abstract
Background: CD33 (Siglec-3) is becoming increasingly important as a target of antibody-mediated therapy in acute myeloid leukaemia (AML). In normal myelopoiesis, expression of CD33 is restricted to advanced stages of differentiation, whereas primitive stem cells do not express CD33. In the present study, we asked whether leukaemic stem cells in patients with AML express CD33.
Materials and methods: A multicolour-staining technique was applied in 11 patients with AML, and leukaemic progenitors defined as CD34(+)/CD38(-)/CD123(+) cells. AML stem cells were purified by cell sorting and were examined for expression of CD33 mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
Results: In all patients in whom the majority of myeloblasts expressed CD33 (n = 8), AML progenitors reacted with the CD33 antibody P67.6. Repopulation experiments utilizing irradiated NOD/SCID mice confirmed that AML stem cells in these patients reside within the CD33(+) subpopulation of the leukaemic clone. Moreover, highly purified AML stem cells (> 98% purity) from patients with CD33(+) AML were found to express CD33 mRNA in RT-PCR analyses. CD33 was neither detectable on CD34(+)/CD38(-) cells in normal bone marrow nor on leukaemic stem cells in patients with CD33-negative AML.
Conclusions: Leukaemic stem cells in patients with CD33(+) AML express CD33. This observation is in favour of novel treatment concepts employing CD33-targeting antibodies in AML.
Similar articles
-
Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.Cytotherapy. 2007;9(2):194-204. doi: 10.1080/14653240601164042. Cytotherapy. 2007. PMID: 17453971
-
Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).Br J Haematol. 2006 May;133(3):337-44. doi: 10.1111/j.1365-2141.2006.06013.x. Br J Haematol. 2006. PMID: 16643437
-
Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.Br J Haematol. 2003 Nov;123(3):420-30. doi: 10.1046/j.1365-2141.2003.04625.x. Br J Haematol. 2003. PMID: 14617000
-
Human leukaemic stem cells: a novel target of therapy.Eur J Clin Invest. 2004 Aug;34 Suppl 2:31-40. doi: 10.1111/j.0960-135X.2004.01368.x. Eur J Clin Invest. 2004. PMID: 15291804 Review.
-
Antibody-targeted therapy for myeloid leukemia.Semin Hematol. 1999 Oct;36(4 Suppl 6):2-8. Semin Hematol. 1999. PMID: 10530710 Review.
Cited by
-
Natural killer cell-based immunotherapy for acute myeloid leukemia.J Hematol Oncol. 2020 Dec 7;13(1):167. doi: 10.1186/s13045-020-00996-x. J Hematol Oncol. 2020. PMID: 33287858 Free PMC article. Review.
-
Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.Int J Mol Sci. 2024 Feb 10;25(4):2150. doi: 10.3390/ijms25042150. Int J Mol Sci. 2024. PMID: 38396825 Free PMC article. Review.
-
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.Oncotarget. 2018 Jan 3;9(11):9706-9713. doi: 10.18632/oncotarget.23880. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515764 Free PMC article.
-
Reciprocal Interactions of Leukemic Cells with Bone Marrow Stromal Cells Promote Enrichment of Leukemic Stem Cell Compartments in Response to Curcumin and Daunorubicin.Asian Pac J Cancer Prev. 2017 Mar 1;18(3):831-840. doi: 10.22034/APJCP.2017.18.3.831. Asian Pac J Cancer Prev. 2017. PMID: 28441794 Free PMC article.
-
Gemtuzumab ozogamicin in acute myeloid leukemia.Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13. Leukemia. 2017. PMID: 28607471 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials